ScholarX: KIM, HEE CHEOL

Detailed Information

KIM, HEE CHEOL (김희철)

Medicine (Medicine)

Research Area

Tel 02-3410-1655
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Colorectal cancer:30||Rectal cancer:24||colorectal cancer:14||Survival:14||Prognosis:10||Colon cancer:10||Recurrence:10||Rectal neoplasms:10||rectal cancer:9||Colorectal neoplasms:7||colon cancer:6||Preoperative chemoradiotherapy:6||Neoadjuvant chemoradiotherapy:6||survival:5||Chemoradiotherapy:4||Laparoscopy:4||Colorectal neoplasm:4||Radiotherapy:4||Chemotherapy:4||Total mesorectal excision:4||prognosis:4||Diseasefree survival:3||Tumor budding:3||Adjuvant chemotherapy:3||Learning curve:3||Metastasis:3||oncologic outcome:3||Colectomy:3||Neoadjuvant therapy:3||recurrence:3||Simvastatin:2||Perineural invasion:2||stage IV:2||Laparoscopic:2||immunohistochemistry:2||MSI:2||Abdominoperineal resection:2||Magnetic resonance imaging:2||Preoperative chemoradiation:2||Mass spectrometry:2||local excision:2||Histological grade:2||Prognostic factor:2||lymph node metastasis:2||anastomotic leakage:2||Stage IIIA:2||Carcinoembryonic antigen:2||Surgery:2||microsatellite instability:2||Leukopenia:2||Radiation effects:2||neoadjuvant chemoradiotherapy:2||chemotherapy:2||Oncologic outcome:2||Local excision:2||colorectal carcinoma:2||colorectal neoplasms:2||Minimally invasive surgery:2||Cetuximab:2||Longterm outcome:2||Overall survival:2||prognostic factor:2||Restaging:2||rectal neoplasm:2||Lymphovascular invasion:2||Risk factor:2||Risk factors:2||Colon:2||Robotic surgical procedures:2||KRAS:2||MMR:2||FOLFOX:2||DNA methylation:1||DSCC1:1||DSML 3: Development/preproduction: Data science output has been rolled out/validated across multiple domains/problems:1||Diabetes:1||Diagnosis:1||Digital sequencing:1||Digital therapeutics:1||Disappearing metastasis:1||Dissection:1||Distal resection margin:1||Double primary malignancies (DPM):1||Downstaging:1||Drug response:1||Drug screening assay:1||Ecadherin:1||ERCC1:1||ERK:1||EYA4 protein:1||Early colon cancer:1||Early detection of cancer:1||Early rectal cancer:1||Elastic netbased machine learning:1||Epigenetics:1||Epithelialmesenchymal transition:1||Exfoliated cancer cells:1||Extraregional lymph nodes:1||FAP:1||FDG PET/CT:1||Familial adenomatous polyposis:1||Fungating tumor:1||Gadoxetic acidenhanced MRI:1||Gastric cancer:1||Genome:1||Genomic profile:1||Genomic test:1||Glasgow prognostic score:1||Handassisted:1||Handassisted laparoscopic anterior resection (HALAR):1||Health informatics:1||Health sciences:1||Hepatectomy:1||Hereditary colorectal cancer:1||High grade:1||Humans:1||Immunoaffinity purification:1||Immunohistochemical markers:1||Immunology:1||Indistinguishable T2/T3:1||Inflammatory bowel disease:1||Inflammatory marker:1||Inguinal:1||Interleukin4:1||Intramucosal carcinoma:1||Intraoperative staging:1||Invasion:1||LINT25:1||Laparoscopicassisted surgery:1||Lateral lymph node:1||Lateral pelvic recurrence:1||Leakage:1||Liver metastases:1||Local:1||Local anesthetics:1||Local recurrence:1||Lymph node metastasis:1||Lymph nodes:1||Lynchlike syndrome:1||MET exon 14 skipping:1||MET monoclonal antibodies:1||MLPA:1||MMP9:1||MR imaging:1||MRI:1||Magnet:1||Mesenchymal stem cell:1||Mesorectalfascia:1||Metastases:1||Metastatic cancer:1||Metastatic colorectal cancer:1||Metformin:1||Methylation array:1||Micropapillary pattern:1||Microsatellite instability:1||Microsatellite instability (MSI):1||Minimally invasive surgical procedures:1||Mobile health:1||Modified complete mesocolic excision:1||Molecular profiling:1||Molecular screening:1||Morbidity:1||Mucinous adenocarcinoma:1||Multiple:1||Muscle contraction:1||MutL homolog 1 (MLH1):1||N staging:1||N,Ndimethylarginine:1||NGS:1||NOTES:1||Neoadjuvant:1||Neoadjuvant chemoradiation therapy:1||Neoadjuvant chemoradiation therapy (CRT):1||Neoadjuvant treatment:1||Neoajduvant treatment:1||Neoplasm staging:1||Neuroendocrine carcinoma:1||Neurotoxicity:1||Nextgeneration sequencing:1||Normal tissues adjacent to tumors:1||OIP5:1||Old age:1||Oncologic outcomes:1||Oncology:1||Open surgery:1||Ovarian metastasis:1||Ovarian metastatectomy:1||Oxaliplatin:1||PDGFRA:1||PET:1||PPI network:1||PRMT6:1||Pancreas:1||Pathologic complete response:1||Pathology:1||Patientderived cell:1||Pelvic recurrencepalliative radiation therapy:1||Physiology:1||Postoperative chemoradiotherapy:1||Postoperative complications:1||Postoperative pain:1||Preoperative chemoradiotherapy:1||Primary tumor:1||Proctectomy:1||Proctocolectomy:1||Promoter methylation:1||Prophylactic:1||Protein arginine methylation:1||Proteinarginine Nmethyltransferases:1||Pseudotime analysis:1||Pulmonary metastasis:1||RAS signature:1||Randomized Controlled Trial:1||Rectal neoplasm:1||Rectal surgery:1||Rectal washout:1||Regorafenib:1||Resection:1||Residual cancer cells:1||Residual tiny metastasis:1||Response:1||Ribonucleic acid sequencing:1||Rightsided colon cancer:1||Robotic TME:1||Robotic surgical procedure:1||Ropivacaine:1||STAT transcription factors:1||Septic:1||Shock:1||Simultaneous liver resection:1||Single port:1||Singleincision:1||Singleincision l:1||Singleincision laparoscopic surgery (SILS):1||Singleport access (SPA):1||Sizebased platform:1||Smads:1||Somatic mutation:1||Sphinctersaving surgery:1||Spleen:1||Stage II:1||Stage II colon cancer:1||Stage IIA colon cancer:1||Stage III colorectal cancer:1||Stage IV:1||Stoma:1||Submucosa:1||Surgery alone:1||Surgery interval:1||Surgical site infection:1||Survival benefit:1||Surviving:1||Synaptophysin:1||Synchronous:1||Systems biology:1||T3N0:1||T3NOMO colon cancer:1||TAP block:1||TNM stage:1||Texture analysis:1||Therapeutic target:1||Thrombophlebitis:1||Thymidylate synthase:1||Transabdominal robotic total mesorectal excision:1||Transanal TME:1||Transanal endoscopic microsurgery:1||Transanal endoscopic total mesorectal excision:1||Transforming growth factor beta:1||Treatment:1||Tumor heterogeneity:1||Tumor regression:1||Tumor response:1||Tumor suppressor gene:1||Tumorinfiltrating immune cells:1||Tumour location:1||Twodimensional gel electrophoresis:1||Twoweek course:1||Type I PRMTs:1||Ubiquitin specific protease 4 (USP4):1||Ulcerative colitis:1||Unresectable metastases:1||Validation:1||Welldifferentiated rectal neuroendocrine tumors:1||Wholeexome sequencing:1||Wide excision:1||Wnt signaling pathway:1||Xenograft:1||Young colorectal cancer:1||acute:1||adjuvant treatment:1||anaplastic lymphoma kinase (ALK) rearrangement:1||anastomotic leak in colorectal surgery:1||angiogenesis:1||betacatenin:1||bevacizumab:1||biomarker:1||bowel movement:1||cancer recurrence:1||carcinoembryonic antigen:1||carcinogenesis:1||cell deconvolution:1||cellfree DNA (cfDNA):1||center dot Lymphovascular invasion:1||chemoradiotherapy:1||cholecystectomy:1||cleaved products:1||clinical course:1||clinical outcome:1||colorectal (colon) cancer:1||colorectal cancer (CRC):1||combination therapy:1||complications of the primary tumor:1||conversion:1||crizotinib:1||cytokines:1||da Vinci SP<sup>®</sup>system:1||digital sequencing:1||distress at the diagnosis:1||drug response:1||early colorectal cancer:1||familial:1||familial colon cancer:1||gastrointestinal malignancies:1||geleluted liquid fraction entrapment electrophoresis (GELPrEE):1||genomewide association study:1||genomic profile:1||genomic test:1||glioma:1||hMLH1:1||handassisted laparoscopic surgery:1||human plasma:1||immune cell proportion:1||immunoaffinity enrichment:1||incomplete obstruction:1||laparoscopic:1||laparoscopic low anterior resection:1||laparoscopic surgery:1||laparoscopy:1||liquid biopsy:1||liver metastasis:1||local recurrence:1||locally advanced rectal cancer (LARC):1||low anterior resection:1||lowmolecularweight (LMW) plasma proteins:1||lymph node:1||lymphadenectomy:1||machine learning:1||magnet:1||magnetic resonance imaging:1||mass spectrometry:1||metastasis:1||methylation:1||mismatch repair deficiency:1||multiomics:1||neoadjuvant CCRT:1||neoadjuvant chemoradiation therapy:1||neuroendocrine tumors:1||next generation sequencing:1||nomogram:1||oncologic outcomes:1||operative time:1||organ invasion:1||p300:1||palliative intervention:1||paraaortic lymph node dissection:1||paraaortic lymph node metastasis:1||paraaortic lymphnode metastasis:1||pathological complete response (pCR):1||pazopanib:1||perineural invasion:1||polymerase:1||posttranslational modification (PTM):1||postoperative chemotherapy:1||postoperative pain:1||preoperative chemoradiotherapy:1||protein arginine methyltransferase 5:1||radiotherapy:1||rectal pain:1||reduced port surgery:1||s disease:1||serosal exposure:1||sidedness:1||single amino acid variation (SAAV):1||single incision laparoscopic surgery:1||single port laparoscopy:1||single port robot:1||singleincision laparoscopic surgery:1||singleincision laparoscopy:1||singlenucleotide polymorphism:1||stage:1||stage III:1||surgical resection:1||survivin:1||symmetric arginine methylation:1||temozolomide:1||thalidomide:1||topdown mass spectrometry:1||total mesorectal excision:1||traction:1||transvaginal:1||tumor deposit:1||tumor infiltrating lymphocytes:1||tumor microenvironment:1||unresectable metastases:1||ADHFE1:1||xenograft:1||AJCC TNM stage:1||AJCC guideline:1||APC gene:1||ATPbased chemotherapy response assay (ATPCRA):1||Adenocarcinoma:1||Adenosine triphosphate:1||Ampliseq:1||Anastomosis:1||Anastomotic leak:1||Anorectal melanoma:1||Anus neoplasms:1||Apoptosis:1||Aptamer:1||Arginine methylation:1||BRAF:1||BRAFV600E mutation:1||Bevacizumab:1||Biocomputational method:1||Bioinformatics:1||Biomarker:1||Biomarkers:1||Bisacodyl:1||CA 199 antigen:1||CAPOX:1||CC chemokine:1||CD133+:1||CEA:1||CMS:1||COVID19:1||CT:1||CTF18:1||CTF1818 module:1||CTHRC1:1||CUSUM:1||Cancer:1||Cancer stem cells:1||Cancer systems biology:1||Candidemia:1||Capecitabine:1||Carcinogenesis:1||Carcinoma in Situ:1||Cellfree DNA (cfDNA):1||Chemoradiation:1||Chemoradiation therapy:1||Chemotherapeutic agent:1||Chest Xray:1||Chromogranin:1||Circulating tumor cells:1||Circumferential resection margin:1||Clinical T4:1||Clinical stage:1||Clinical trials:1||Colon neoplasm:1||Colonic neoplasms:1||Colonoscopic resection:1||Colorectal:1||Colorectal cancer surgery:1||Colorectal cancer with liver metastases:1||Colorectal liver metastasis:1||Colorectal surgery:1||Complete remission:1||Complications:1||Computed tomography:1||Concurrent chemoradiotherapy:1||Conventional laparoscopic anterior resection (CLAR):1||Conversion:1||CpG island methylator phenotype (CIMP):1||Crohn&apos:1||Cystadenocarcinoma:1||Cytokeratin:1||D:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE